Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching

doi:10.4239/wjd.116477

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

(0)

(6)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Jun 15, 2026; 17(6): 116477
Published online Jun 15, 2026. doi: 10.4239/wjd.116477

Open in New Tab Full Size Figure Download Figure

Figure 1 Glucagon-like peptide-1 receptor agonists and polyagonists. GLP-1: Glucagon-like peptide-1; GIP: Glucose-dependent insulinotropic polypeptide.

Open in New Tab Full Size Figure Download Figure

Figure 2 The rationale for switching glucagon-like peptide-1 receptor agonists. GLP-1: Glucagon-like peptide-1; HbA1c: Glycated hemoglobin.

Citation: Ganakumar V, Fernandez CJ, Pappachan JM. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching. World J Diabetes 2026; 17(6): 116477
URL: https://www.wjgnet.com/1948-9358/full/v17/i6/116477.htm
DOI: https://dx.doi.org/10.4239/wjd.116477

Ganakumar V, Fernandez CJ, Pappachan JM. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching. World J Diabetes 2026; 17(6): 116477 [DOI: 10.4239/wjd.116477]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.